WuXi Biologics (Cayman) Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de WuXi Biologics (Cayman) de 14.2% y 13% por año respectivamente. Se prevé que el BPA crezca en un 13.6% al año. Se espera que la rentabilidad financiera sea de 10.3% en 3 años.

Información clave

14.1%

Tasa de crecimiento de los beneficios

13.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	21.7%
Tasa de crecimiento de los ingresos	13.0%
Rentabilidad financiera futura	10.2%
Cobertura de analistas	Good
Última actualización	19 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:1FW2 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	24,316	5,481	2,046	7,133	22
12/31/2025	21,725	4,916	2,265	6,774	29
12/31/2024	18,160	3,881	321	5,934	24
12/31/2023	17,034	3,400	612	4,668	N/A
9/30/2023	16,794	3,776	N/A	N/A	N/A
6/30/2023	16,554	4,152	N/A	N/A	N/A
3/31/2023	15,911	4,286	N/A	N/A	N/A
12/31/2022	15,269	4,420	-327	5,542	N/A
9/30/2022	14,179	4,251	N/A	N/A	N/A
6/30/2022	13,090	4,081	-1,028	4,091	N/A
3/31/2022	11,690	3,735	-2,052	3,761	N/A
12/31/2021	10,290	3,388	-3,077	3,431	N/A
9/30/2021	9,183	3,092	-4,006	2,840	N/A
6/30/2021	8,075	2,795	-4,936	2,249	N/A
3/31/2021	6,844	2,242	-4,540	2,065	N/A
12/31/2020	5,612	1,689	-4,144	1,881	N/A
9/30/2020	4,967	1,494	-4,049	1,649	N/A
6/30/2020	4,321	1,300	-3,954	1,417	N/A
3/31/2020	4,152	1,157	-2,979	1,312	N/A
12/31/2019	3,984	1,014	-2,004	1,208	N/A
9/30/2019	3,535	922	-1,356	1,035	N/A
6/30/2019	3,087	831	-708	861	N/A
3/31/2019	2,811	731	-810	811	N/A
12/31/2018	2,534	631	-912	762	N/A
9/30/2018	2,277	520	-1,004	508	N/A
6/30/2018	2,019	410	-1,096	255	N/A
3/31/2018	1,819	331	-712	308	N/A
12/31/2017	1,619	253	-327	360	N/A
9/30/2017	1,429	177	N/A	320	N/A
6/30/2017	1,233	149	N/A	369	N/A
3/31/2017	1,111	145	N/A	226	N/A
12/31/2016	989	141	N/A	82	N/A
9/30/2016	889	171	N/A	162	N/A
12/31/2015	557	45	N/A	107	N/A
12/31/2014	332	42	N/A	22	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (14.2% al año) de 1FW2 es superior a la tasa de ahorro (0.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (14.2% al año) de 1FW2 crezcan menos que el mercado German (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 1FW2 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (13% al año) de 1FW2 crezcan más rápidamente que los del mercado German (5.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13% al año) de 1FW2 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 1FW2 sea baja dentro de 3 años (10.3%).

WuXi Biologics (Cayman) Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: CN¥0.82 (vs CN¥1.06 in FY 2022)

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

Investor sentiment deteriorates as stock falls 17%

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 16%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

Investor sentiment improves as stock rises 16%

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 32%

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Board Member recently sold €2.9m worth of stock

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

Investor sentiment deteriorates as stock falls 22%

Now 23% undervalued after recent price drop

CEO & Executive Director recently sold €1.5m worth of stock

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.81 in FY 2021)

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold €740k worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

Now 21% undervalued

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Now 21% undervalued

CEO & Executive Director recently sold €2.1m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥0.81 (vs CN¥0.43 in FY 2020)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento